Lobe科学获得全欧盟的白血病专利,该专利是治疗镰状细胞疾病脂肪酸缺乏的治疗方法。 Lobe Sciences gains EU-wide patent for Altemia®, a treatment for fatty acid deficiencies in Sickle Cell Disease.

一家生物制药公司Lobe Science(Lobe Sciences)为治疗镰状细胞疾病(SCD)的基于DHA的成分获得了欧洲单一专利权。 Lobe Sciences, a biopharmaceutical company, has secured a European Unitary Patent for its DHA-based composition that treats Sickle Cell Disease (SCD). 这项专利涵盖欧盟17个国家,保护Altemia®,这是一种旨在解决SCD患者脂肪酸缺乏症的医疗食品. The patent, covering 17 EU countries, protects Altemia®, a medical food designed to address fatty acid deficiencies in SCD patients. 这一验证加强了Lobe的知识产权,为整个欧洲更广泛的商业化铺平了道路。 This validation strengthens Lobe's intellectual property and paves the way for broader commercialization across Europe.